FASEB SRC on Autoimmunity

项目总结 在过去的几年里，我们对本病致病机制的了解有了巨大的增长。 自身免疫，并重新认识不同免疫之间的相似和重要区别 自身免疫性疾病。自身免疫研究的快速发展领域的例子是识别和 分泌独特炎症介质的新的致病T细胞亚群的特征和新的 对遗传易感性、环境压力和微生物组之间的界面的洞察和 代谢体。这些发现在很大程度上是基础科学家的工作成果，而这项FASE B科学 关于自身免疫的会议历来侧重于讨论基础研究的新发现 自身免疫力。然而，我们认为，对于基础科学家来说，建立和保持联系是至关重要的 致那些致力于将机制转化为治疗靶点的科学家。例如，意想不到的 治疗性B细胞去除在一些自身免疫性疾病中的疗效已促使人们加紧研究 基础科学家研究B细胞在致病途径中的作用。以同样的方式，对角色的理解 影响免疫调节的微生物群的研究导致了潜在的 针对其他疾病的新治疗策略，如炎症性肠病和类风湿性关节炎。 关于调节性和效应性T细胞新陈代谢的基本信息激发了人们对推动 代谢操纵作为治疗策略，不仅在癌症中，而且在自身免疫方面也是如此。因此， 在保持对自身免疫前沿基础研究的关注的同时，我们将继续 发表演讲的翻译科学家专注于人类自身免疫性疾病中组织损伤的机制， 这将讨论治疗自身免疫性疾病的新策略，以及关于成功和 操纵自身免疫性人类免疫系统的失败。我们希望把重点放在治疗上 自身免疫性疾病的治疗将吸引基础和行业科学家，并将强烈刺激 初级和老牌调查人员都感兴趣。这次会议的规模和背景非常适合 促进开放的数据交换和思想的交叉滋养，这将激发新的假设和 自身免疫研究方向。

PROJECT SUMMARY There has been enormous growth in the past few years in our understanding of pathogenic mechanisms in autoimmunity, and a new recognition of the similarities and important differences between different autoimmune diseases. Examples of rapidly moving areas of research in autoimmunity are the identification and characterization of new subsets of pathogenic T cells that secrete unique inflammatory mediators and novel insights into the interface between genetic susceptibility, environmental stress, and the microbiome and metabolome. These findings have emerged largely from the work of basic scientists, and this FASEB science conference on Autoimmunity has historically focused on discussion of new findings in basic research in autoimmunity. However, we believe that it is crucial for basic scientists to establish and maintain connections to scientists who are working to translate mechanisms into therapeutic targets. For example, the unexpected efficacy of therapeutic B cell depletion in some autoimmune diseases has prompted intense investigation by basic scientists into the role of B cells in pathogenic pathways. In a like manner, the understanding of the role of the microbiome influencing immune regulation has led to the discussion and development of potentially novel therapeutic strategies for other illness, such as inflammatory bowel disease and rheumatoid arthritis. Basic information on metabolism in regulatory and effect T cells has spurred interest in the drive toward metabolic manipulations as therapeutic strategies, not only in cancer, but also in autoimmunity. Therefore, while maintaining a focus on cutting edge basic research in autoimmunity, we will continue to have as speakers translational scientists that focus upon mechanisms of tissue injury in human autoimmune diseases, and that will discuss new strategies for treating autoimmune diseases and current data on the successes and failures of manipulating the immune system in autoimmune humans. We expect that emphasis on therapeutic treatment of autoimmune disease will attract both basic and industry scientists, and will stimulate strong interest among both junior and established investigators. The size and setting of this meeting are ideal to promote the open exchange of data and cross-fertilization of ideas that will stimulate new hypotheses and directions in autoimmunity research.